Recordati Overview
- Founded
-
1926
- Status
-
Public
- Employees
-
4,300
- Stock Symbol
-
REC
- Investments
-
21
- Share Price
-
$43.90
- (As of Friday Closing)
Recordati General Information
Description
Recordati SpA is a drug manufacturing company that focuses on specialty pharmaceuticals. The company produces and promotes medicines globally that focus on primary-care therapies and rare diseases. Recordati uses strategic partnerships as part of its long-term growth strategy. The vast majority of the company's revenue is generated in Italy, followed by France and Germany. Recordati reports two operating segments: Specialty and Primary care and Rare diseases. The bulk of the company's profit is derived from its specialty and primary care segment, which includes the production of active ingredients.
Contact Information
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
MIL
Primary Office
- Via Matteo Civitali, 1
- 20148 Milan
- Italy
+39 02 000000
Recordati Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $43.90 | $44.03 | $33.51 - $56.15 | $9B | 205M | 208K | $1.74 |
Recordati Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 9,134,386 | 14,008,795 | 12,480,515 | 9,142,629 |
| Revenue | 1,949,048 | 1,868,119 | 1,651,582 | 1,658,847 |
| EBITDA | 607,794 | 683,787 | 646,138 | 601,557 |
| Net Income | 358,165 | 456,327 | 404,651 | 412,879 |
| Total Assets | 3,909,785 | 3,188,559 | 3,335,245 | 3,146,485 |
| Total Debt | 1,671,232 | 1,123,379 | 1,305,067 | 1,232,809 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Recordati Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Recordati Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Recordati SpA is a drug manufacturing company that focuses on specialty pharmaceuticals. The company produces and promot
Pharmaceuticals
Milan, Italy
4,300
As of 2023
0.000
0000-00-00
000000000000
00000
iquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in volupta
0000 000000000
Mumbai, India
00000
As of 0000
00000000
000000
ud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis au
0000 000000000
Daix, France
000
As of 0000
00000
00000000
00000
Add Comparison
Recordati Competitors (55)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cipla | Corporation | Mumbai, India | 00000 | 00000000 | ||
| 000000000 000000 | Corporation | Daix, France | 000 | 00000 | 00000000 | 00000 |
| 0000000000 0000000 | Corporation | Ingelheim am Rhein, Germany | 00000 | |||
| 00000 000000000000 | Private Equity-Backed | Ahmedabad, India | 00000 | 000.00 | 00000000000 | 000.00 |
| 00000000 000000 | Corporation | Tokyo, Japan | 00000 | 00000000 |
Recordati Patents
Recordati Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20200397728-A1 | Pharmaceutical formulation for carglumic acid | Inactive | 30-May-2019 | 0000000000 | |
| US-20220071938-A1 | Treatment of hyperammonemia in patients with renal insufficiency | Inactive | 22-May-2019 | 0000000000 | |
| US-20220040129-A1 | Treatment of hyperammonemia in patients with renal insufficiency | Inactive | 22-May-2019 | 0000000000 | |
| EP-3972580-A1 | Treatment of hyperammonemia in patients with renal insufficiency | Pending | 22-May-2019 | 0000000000 | |
| US-20200368192-A1 | Treatment of hyperammonemia in patients with renal insufficiency | Inactive | 22-May-2019 | A61K31/197 |
Recordati Executive Team (10)
Recordati Board Members (10)
| Name | Representing | Role | Since |
|---|---|---|---|
| 0000000 000000000 | Self | Board Member | 000 0000 |
| 000000 000000000 | Recordati | Board Member | 000 0000 |
| 00000 0000000 | Recordati | Board Member & General Manager | 000 0000 |
| 00000 00000 | Self | Board Member & Vice Chairman | 000 0000 |
| 000 00000000 | Self | Board Member | 000 0000 |
Recordati Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Recordati Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Recordati Investments & Acquisitions (21)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000 000000 | 16-Mar-2022 | 0000000000 | 00000 | Pharmaceuticals | 00000000 |
| 00000000 (000 | 23-Oct-2019 | 000000000 | 00000 | Buildings and Property | 0000000 0 |
| 000000000 | 31-Dec-2018 | 0000000000 | 000.00 | Pharmaceuticals | 000000 00 |
| 0000000 00000 | 11-Jun-2018 | 0000000000 | 000.00 | Food Products | 0000000 0 |
| Three Bayer Consumer Health Brands (Ransipeg, TransipegLib and Colopeg) | 18-Dec-2017 | Corporate Asset Purchase | 000.00 | Buildings and Property | 000000 00 |
Recordati Subsidiaries (6)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| EUSA Pharma | Pharmaceuticals | Hemel Hempstead, United Kingdom | 2006 |
| 0000000 00000 | Food Products | Milan, Italy | 0000 |
| 000000000 | Pharmaceuticals | Boulogne, France | 0000 |
| 000000 000000 | Pharmaceuticals | Puteaux, France | 0000 |
| 00000 00000 000000 | Pharmaceuticals | Madrid, Spain | 0000 |
Recordati ESG
Risk Overview
Risk Rating
Updated September, 30, 2022
28.23 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,638
Rank
00.00
Percentile
Pharmaceuticals
Industry
00 of 1,008
Rank
00.00
Percentile
Pharmaceuticals
Subindustry
00 of 473
Rank
0.00
Percentile
Recordati Exits (1)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 00000000000000 | 01-Jan-1986 | 000000000000000000 | Completed |
|